Enhancement of depressed lymphokine activated killer cell activity in patients with hepatocellular carcinoma

Biotherapy. 1990;2(1):1-12. doi: 10.1007/BF02172071.

Abstract

Hepatocellular carcinoma (HCC) patients can be divided into two groups according to the degree of lymphokine activated killer (LAK) cell activity; a high LAK activity group (H-LAK-HCC) and a low LAK activity group (L-LAK-HCC). Interferon-gamma (IFN-gamma) production is severely defective in L-LAK-HCC but not defective in H-LAH-HCC. IFN-gamma production is suppressed with the addition of anti-Tac in dose dependent manner, though LAK activity is suppressed only in the presence of high concentration of anti-Tac. LAK activity is suppressed with the addition of anti-IFN-gamma, which is most prominent when the antibody is present during the first 12 hr of incubation. LAK generation is enhanced with the addition of recombinant IFN-gamma, which is most prominent when it is present during the first 12 hr of incubation. However, this enhancing effect is less prominent in L-LAK-HCC as compared to normals, liver cirrhosis, and H-LAK-HCC. This enhancement is regarded to depend on the presence of Leu7+ and Leu11+ subset, as this enhancement is abandoned and IFN-gamma production is inhibited when either of these subsets is deleted. These data suggest that IFN-gamma production and the participation of Leu7+ and Leu11+ subsets is important in sufficient LAK generation, and that poor IFN-gamma production and insufficient response to IFN-gamma may be the cause of severely defective LAK generation in L-LAK-HCC.

MeSH terms

  • Aged
  • Carcinoma, Hepatocellular / immunology
  • Carcinoma, Hepatocellular / metabolism*
  • Carcinoma, Hepatocellular / therapy
  • Female
  • HeLa Cells
  • Humans
  • Interferon-gamma / antagonists & inhibitors
  • Interferon-gamma / biosynthesis*
  • Interferon-gamma / immunology
  • Interferon-gamma / pharmacology
  • Interleukin-2 / pharmacology*
  • Interleukin-2 / therapeutic use
  • Killer Cells, Lymphokine-Activated / drug effects
  • Killer Cells, Lymphokine-Activated / immunology
  • Killer Cells, Lymphokine-Activated / metabolism*
  • Liver Cirrhosis / immunology
  • Liver Cirrhosis / metabolism
  • Liver Neoplasms / immunology
  • Liver Neoplasms / metabolism*
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Recombinant Proteins / pharmacology

Substances

  • Interleukin-2
  • Recombinant Proteins
  • Interferon-gamma